Collabrx (CLRX) Misses Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall St muted as markets monitor Hormuz situation; data awaited
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil rises 3% as Iran tempers hopes of Hormuz reopening
- Intel stock stumbles following blockbuster $15 billion equity offering
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
CollabRx Reports First Quarter Fiscal Year 2015 Financial Results
August 14, 2014 4:00 PM EDTSAN FRANCISCO, Aug. 14, 2014 (GLOBE NEWSWIRE) -- CollabRx, Inc. (the "Company") (Nasdaq: CLRX) announces financial results and business highlights for the first quarter of fiscal year 2015, which ended June 30, 2014.
First Quarter Business Highlights
Throughout the first fiscal quarter, the Company made significant progress in building a strong base for future revenues and establishing a leadership position among oncologists and pathologists in the rapidly emerging area of clinical genetic testing in cancer, including:
Entering into agreements with additional diagnostic and specialty laboratories for its Genetic Variant Annotation (GVA) Service, including The Jackson... More